Strategic Management - Strategy evaluation

This report on Strategic Management and Strategy evaluation discusses the UK and global pharmaceutical industry frameworks and competitive environment analysis of Astra Zeneca. It includes a PESTLE analysis, Porter's Five Forces analysis, SWOT analysis, and Strategic Group analysis. The report also provides an overview of Astra Zeneca and its innovative medical drugs and services. Subject: Strategic Management, Course Code: NA, Course Name: NA, College/University: NA

Strategic Management -
Strategy evaluation

TABLE OF CONTENT
INTRODUCTION...........................................................................................................................3
Overview of Astra Zeneca...............................................................................................................4
UK and global pharmaceutical industry frameworks..................................................................5
Competitive environment analysis of Astra Zeneca....................................................................9
REFRENCES.................................................................................................................................14

INTRODUCTION

Strategic management and strategy evaluation can be understood as widely essential
aspect, which plays strong role in bringing forward high scale competencies variedly within
functional evolved industry paradigms. AstraZeneca, has been taken as the pharmaceutical
company in this study which is one of the top rated brand having vast global pharmaceutical
services. The brand is one of the most innovative trusted brand, having vast products in medical
industry drugs categories, which has enhanced stronger engagement within industry targets
diversely. Within recent time of Covid -19, Astra Zeneca has rose as one of the best trustworthy
pharmaceutical company having varied medical drugs, and services related to medical expertise.
The report will explain varied aspects related to UK and global competitive pharmaceutical
industry frameworks, where main scope is pertained towards high scale business competencies
fundamentally. Research will also extensively evolve rise on bringing competitive environment
analysis based on latest productive services, higher scale rapid technical strengthened rise which
rapidly diversifies extensive growth.
Overview of Astra Zeneca
Astra Zeneca is British Multinational Pharmaceutical company having headquarters in
England, known for world class best pharmaceutical services and high scale advanced
technologies used in production expertise targets diversely. The brand has been witnessing high
scale expertise in technical strengthened best benchmarks profoundly, where medicines and
drugs are highly advanced and also productively innovative. It can be also understood that Astra
Zeneca has been excelling towards best technical productive targets and high advanced
competencies rapidly, for larger scale expertise targets within business goals.
Overview of Astra Zeneca also enables us to attain significant focus towards new
breakthrough achieved in global products and strategies, which has enhanced strong brand value
actively. There is stringent rise upon commercial channels within pharmaceutical operations, and
business operated scientific activities based on specific frameworks (Mitchell and et.al, 2021).
There has been also diverse rise achieved on exponential business paradigms, where
determinants correlated for stringent rise based on operational parameters open up scope for
larger scale expertise technical goals within. Investments in company are highly correlated to
generate stronger brand value, larger innovative positioning goals and be technically advanced

for technical best productive strengthened rise. Astra Zeneca is also leading towards best
pharmaceutical services and drugs, which has also exponentially enabled bran value to be
enhanced innovatively within key business channels informatively. It can be also understood that
the company has best scale business goals within engaging towards extended commercial
expertise targets, which further has evolved company outlook to rise diversely (Mallapaty and
Callaway, 2021).
.
UK and global pharmaceutical industry frameworks
Global pharmaceutical market has been witnessing high boost in recent years, where
2020 specifically is valued to be variedly dynamically growing and has revenue expanded over
1.27 trillion. The UK and global pharmaceutical industry is wide having various new functional
rapid innovations in medical drugs and medical services, based on recent functional innovation
standards. Astra Zeneca, being one of the best company also faces strong competitive
environment rapidly where models and strategic innovation, plays strong role to be analyzed and
practically discussed for higher business engagement. The company has best global positioning
scenarios pertaining towards new competencies diversely, where Astra Zeneca has been
surpassing best industry productive goodwill scenarios within industry targets. Brand also deals
with customized specific high tech innovative expertise technical targets for channelizing new
strengthened rise, which further technically diversifies strengthened rise (16 Strategic Planning
Models To Consider. 2021).
Pestle analysis model:
Pestle model is also one of the finest business strategic model, potentially heading for
gaining larger scale rise diversely based on optimum targets functionally. External industry
analysis, further will enable to identify new best scale targets for generating best scope diversely
and enhanced functional expertise paradigms. External business environment plays strong role
for bringing on best functional engagement criteria diversely, based on industry paradigms
actively to strengthen up potential usage of key resources variedly.

 Political factors: Astra Zaneca has strong international market presence, where political
stability among various countries political scenarios also plays strong role to be
maintained rapidly. Also, political scenarios are widely crucial where external
international company business scenarios are imperative to be focused on for larger
expertise oriented benchmarks rapidly (Ladas, Kavadias and Loch, 2021). Economic factors: Global economic fluctuations, productivity in the economy and
inflation rates, interest rates are some of the most vital aspects where growth along with
stability on business operations are focused on. Astra Zaneca with varied changing best
pharmaceutical services around world, aims to bring on wider scale competitive services.
International economic currency parameters, and varied extensive commercialization
growth excessively evolving among recent years further opens up scope for extended
commercial stability. Social factors: With latest demands and preferences among recent changes coming up in
pharmaceutical industry external competitive environment within industry is also
variedly expanding. Social factors further also evolve rise towards keen untapped new
goals, enhance rapid key potentialities and bring on best expertise for dynamic growth
competencies. Covid -19 related social factors also plays strong role to synchronize best
determinants rapidly and bring on best operatives, where Astra Zeneca investments are
also rapidly informative
 Technology factors: Recent changes in technology advancement strategies, impact
coming up by innovation in technology upgradation has high scale exposure and positive
impact to be evolved within Asrtra Zeneca business goals. The company also has long
term technical productivity targets, for extended competitive work goals rapidly where
Astra Zeneca has high scope imperatively. UK and global companies are taking up new
steps with artificial technology adoption, where usage of best technicality further opens
up scope for larger scale expansion (Géhin and Holman, 2021). Legal factors: The global competitive environment, within pharmaceutical industry
heads on strong focus for keeping up with copyright laws, patents and intellectual rights
which further enhances stronger productive outlook. Data protection and health safety
laws, are also some of the key factors which practically opens up scope for extensive
productive growth standards.

 Environment factors: CSR factors and sustainability aspects have high role for further
bringing on ecofriendly strategies, which further plays primitive aspect in strengthening
productive role diversely. Astra Zeneca has strong environmental factors, having strong
brand productivity for extended commercial expanded criteria which further enhances
scope for larger business engagement.
The above analyzed aspects in pestle analysis further adds to productive
determinants, based on channelized scale targets for stringent rise variedly which further
heads on profound focus for strengthened business competencies. Astra Zeneca, as one of
the best pharmaceutical brand, has engaged strong productive outlook within competitive
global industry horizons which extensively has evolved competitive rise diversely. The
brand has been operatively heading on towards best usage of high scale competitive new
strategies, engaging on towards expertise targets within longer run for strategic advanced
goals (Bhaskarabhatla and et.al, 2021).
Five forces analysis model
Porter five force model is one of the best framework, for gaining stronger competitive
analysis done in proper structured format variedly based on innovative functional channels
rapidly. External industry factors have high scope, for strengthened business rise goals
imperatively which examines key productive focus for strengthened engaged scenarios actively
within longer run (Mahase, 2021). Astra Zeneca uses five force model to gain productivity
engaged on rapidly, and bring on best drugs services for larger functional growth paradigms
dynamically. Threat of new entrants (High) : Pharmaceutical industry is variedly innovative and
competitively growing, where new brands and companies are entering rapidly which
further impacts on stronger business benchmarks. Entrants have stronger business quality
perspectives, where Astra Zeneca has been competently growing for functional
engagement rapidly which further significantly addresses new scale diversity among
business productivity. Threat of supplier’s power (Low): Astra Zeneca has strong independent suppliers chain,
which heads on strong focus for leveraging functional rise diversely based on optimum

efficacy aspects variedly. The suppliers power has been competently engaging as per
varied scale functional targets, bringing rapid engagement for strong supply chain
structure. The suppliers power is also low due to best supply structure targets, enhance
competitive positioning and stronger business outlook confidently (Larkin and et.al,
2021). Threat of substitution (Medium): The power is limited as Astra Zeneca has promising
quality for best consumer’s benchmarks within pharmaceutical industry domains, where
threat of substitution is limited. Brand goodwill is also variedly strong, engaged on best
innovative rapid technology services which has enabled company to extensively expand
among productive channels rapidly. Substitution factors holds specific importance for
leveraged functional rise diversely, which further also opens up scope towards extended
commercial growth. Threat of buyer’s power (low) : The company medical drug services are widely
advanced, based on buyer’s preferences where buyer power determines strong focus for
strengthened functional engagement expertise dynamically. Buyers have high strong
preferences, which has enhanced company business services for larger scale
diversification and innovative business positioning within global pharmaceutical industry
targets.
 Competitive rivalry (Medium): Astra Zeneca on basis of strong competitive rivalry has
strong brand image, where competitive parameters have been fundamentally expanding
on new scenarios dynamically. The pharmaceutical industry is rapidly evolving, on terms
of high exposure and keen untapped fundamental goals which further synchronizes focus
towards best channelized paradigms (Dyer, 2021).
The competitive factors analysis, as per varied scale expansion variedly heading on
towards Astra Zeneca business goals have enabled to evaluate strong brand positioning with
strong goodwill and high revenue long term goals. Porter five force analysis has examined
determinants to be evaluated diversely, strengthened vision and competitive paradigms to rise
variedly based on competitive frameworks. Porter model implementation, has extended new
functional scenarios based upon new medical sciences goals within pharmaceutical sector goals
within longer term. This also heads on functional rise profoundly to bring on critical evolvement
rapidly within functional growth primitive benchmarks which has rapidly expanded key

determinants. It also plays strong role to extensively bring on competitive rise for higher scale
rise within channels, which has operatively enhanced evolved competitive abilities.
Competitive environment analysis of Astra Zeneca
The competitive environment analysis, will further expand keen focus towards rapid
engagement variedly based on expertise rise targets which enables efficacy to grow actively.
Swot model analysis, will rapidly enable company to gain best revenue rise in future competitive
engagement goals expertise and gain higher customer revenue. This further also heads on
strengthened rise for larger scale extended business goals and untapped functional paradigms,
which further plays crucial role among functional targets dynamically. Brand has been also
succeeding to bring on native Astra Zeneca actions new resources, and competence based
businesses to bring on extended commercial growth parameters for successfully completing best
medical services variedly (Schmuck, 2021).
SWOT model:
 Strengths: Astra Zeneca is one of the best pharmaceutical company having strong brand
goodwill, high acclaimed value within global benchmarks which has enhanced high scale
competencies diversely. The brand also further uses strong competent business goals,
where recent drug formation pertaining to covid 19 vaccination has enhanced brand
image variedly within global aspects rapidly. Weaknesses: Astra Zeneca drugs and medications are costly, which has reduced
practical reach among all parts of world rapidly for strengthened working competencies
variedly. There is also weakness on terms of high scale functional synergies to expand
key business goals extensively, bring rapid new investment levels and gain best targets
advancing.
 Opportunities: There is high scale opportunity, to further diversify innovations rapidly in
medication facilities and also attain operative growth functionally for new strengthened
vision. Astra Zeneca has been also witnessing competitive engagement among new plans,
where resources structured formation further expands scope for larger commercial growth
engagement (Ben‐Jebara and Modi, 2021).

 Threats: There is threat of competitive brands diversification within global
pharmaceutical industry, which has imposed strong positioning parameters rapidly for
untapped wider business targets. Threat of strengthened varied expertise, opens up scope
to gain best primitive untapped scenarios functionally which further will scale up
extensive commercial success.
The Astra Zeneca company has been integrating best channels of innovative resources,
strong business competencies and capabilities where benefits of strategic competitive
positioning, global expertise determinants has leveraged best goals rapidly. This further has also
expanded key new technologies, revitalizing larger markets diversely on stronger operational
goals. This also shows that determinants related to strengthened best scale best targets, for large
scale efficacy which has extended high goodwill diversely. Astra Zeneca has been also investing
further to bring on best drugs potentially, higher operational growth structured goals for larger
scale expertise competencies variedly within new channels targets (Sunsandee, Phatanasri and
Pancharoen, 2021).
Strategic Group analysis
The SGA analysis, heads on towards identifying competitive environment and underlying
new factors for larger profitability goals within longer run in competitive industry.
Pharmaceutical industry, has been engaging towards best productive rise diversely on significant
new expertise targets where structure, profitability factors and project keen phenomenon
scenarios are evocatively growing (Baker, 2021). Astra Zeneca develops strong manufacturing
drugs, based on new medical conditions and demands evolving within recent time period which
has enhanced strong brand identity diversely. It has been also continually researching and
developing new treatments in serious diseases, which has extended lab medicines for stringent
manufacturing proceedings diversely based on latest targets.
Strategic group analysis model, also heads on functional focus for technical expansion
diversely on optimum synergies rapidly and extended market percentage is highly advanced.
Stringent innovative environment within Astra Zeneca further has been competitively engaging
to bring on rapid new machinery diversification scenarios, where business goals are also
practically worked. The growth of business has been also found to be diversely strong, recurring
towards cost effective new business technical expertise targets for larger scale imperative

paradigms. Astra Zeneca, being UK third pharmaceutical company has been characterized with
strong competitiveness where integral engagement towards science, technology innovation and
stronger brand image is practically focused on. Astra Zeneca has been witnessing promising
growth variedly, based on optimum challenging expertise targets by delivering best resourceful
value among services and also practically being one of the best trustable brand (Asfahani, 2021).
Industry life cycle:
The industry life cycle consists of various stages, which are based on business plans
formation and productive implementation rise diversely which further heads focus for gaining
stronger brand positioning actively. Covid-19, global pandemic has hit hard where
pharmaceutical industry is rapidly expanding keenly within new paradigms diversely within new
expertise oriented technical domains. Astra Zeneca by implementing industry life cycle, will be
able to bring on exponential rise diversely by bringing productive rise diversely on functional
engagement variedly (Ambituuni, Azizsafaei and Keegan, 2021). Start-up: Astra Zeneca invests best resources for planning up new resources innovatively
where investments are significantly correlated to bring on productive engagement as per
varied untapped paradigms diversely. First step within start up, profoundly heads on
productive focus for extended rise based on larger scale rise diversely and correlated for
best technical efficacy within longer run.
 Growth: At this stage, Astra Zeneca builds best change management tools and growth
functional strategies for dynamic business rise effectively which has exponentially
evolved competent brand engagement rapidly. Astra Zeneca has best technical
determinants, expanded among longer scale productive changes based on pharmaceutical
industry frameworks functionally for extended competent synergies. Shakeout: The brand identifies key directive targets and challenging competitive
technical scenarios, which further plays strong role for building higher key industry
positioning variedly. Shakeout factor, also is essential to yield on best technical
engagement and yield best targets within longer run for strengthened functional
productivity.
 Maturity: This stage holds huge essential importance for industry competitive market
stability, where Astra Zeneca has best market products in forms of advanced medical

drugs and services. Maturity factor also holds primitive importance for strengthened rise,
which will sub scale integrative new paradigms diversely which further strengthens larger
scale competencies (Zhu, Ninh, and Liu, 2021). Decline: New changes at this company may face decline among operations, where
strengthened vision and significant focus on varied customer’s preferences hold high
essential role to enhance engaged brand value. Astra Zeneca has been optimistically
expanding towards best new primitive functional paradigms, which further brings on
extensive paradigms rise diversely for extended commercial success.
From the above discussed stages within industry life cycle stages, it has been found up that Astra
Zeneca has been witnessing best scale targets for larger primitive growth paradigms dynamically
and also gas best commercial productive outlook within pharmaceutical industry. The company
has best work potentialities, higher competitive plans for evolving towards best drug formation
and services for attaining optimum efficacy within longer run targets dynamically (Wise, 2021).
Best dynamic capabilities of Astra Zeneca
The brand develops best manufactured range of best innovative drugs and new integrated
aspects, correlated towards high scale medical targets for extended new research goals for
presenting innovative new plans. Related to recent Covid -19, medical specific requirements the
company investments are highly fruitful for attaining towards specific efficacy competencies
within rapid active growth in revenue rise.
 Astra Zeneca spends fortune amount where medical expertise and diagnosis of best
pharmaceutical drugs has evolved rapid rise diversely within best targets actively. It can
be also extensively understood that brand has been expanding best human resources
expertise variedly on terms of new plans, high tech competitive channels for strategic
operational scope which further opens up scope variedly (AstraZeneca advances response
to global COVID-19 challenge as it receives first commitments for Oxford’s potential
new vaccine, 2020).
 Brand aims to further enhance operative functional rise proactively, for extended new
significant functional rise based on bringing best drugs for advanced medical reasons.
The Covid – 19 vaccine is also one of the key benchmark achieved by company medical
and pharmacy specialists which is one of the key functional growth achieved in field by

company. It can be also understood that company has been strongly heading to bring on
new cost investments, based on high scale diversification for extensive new competencies
engagement goals. There is also productive scope to channelize new productive
advancement innovatively on extended new channels, based on rapid engagement targets.
CONCLUSION
Astra Zeneca has evolved rapidly as one of the best brand in global industry, where from
the above analyzed aspects in report, it can be concluded that Astra Zeneca being one of the best
pharmaceutical company in global scenarios has high scale business competencies within
diversified fields for serving best goals. The research within study also has concluded that Astra
Zeneca, has best competitive medical products and services for extended competitive business
proceedings. Report has also concluded further brand innovative positioning, best usage of high
scale advanced drugs and implementation rise profoundly where higher competitive positioning
further revamps larger analytical engagement. Study further also correlates focus on extended
usage of best models, which are swot, pestle and porter analysis functionally evolving rise
imperatively for untapped commercial growth techniques.

REFRENCES
Books and Journals
Ambituuni, A., Azizsafaei, F. and Keegan, A., 2021. HRM operational models and practices to
enable strategic agility in PBOs: Managing paradoxical tensions. Journal of
Business Research. 133. pp.170-182.
Asfahani, A., 2021. THE IMPACT OF MODERN STRATEGIC HUMAN RESOURCES
MANAGEMENT MODELS ON PROMOTING ORGANIZATIONAL
AGILITY. Academy of Strategic Management Journal. 20(2). pp.1-11.
Baker, D., 2021. The Future of the Pharmaceutical Industry: Beyond Government-Granted
Monopolies. Journal of Law, Medicine & Ethics, 49(1), pp.25-29.
Ben‐Jebara, M. and Modi, S.B., 2021. Product personalization and firm performance: An
empirical analysis of the pharmaceutical industry. Journal of Operations
Management, 67(1), pp.82-104.
Bhaskarabhatla, A., and et.al, 2021. How Does Regulation Impact Strategic Repositioning by
Firms Across Submarkets? Evidence from the Indian Pharmaceutical
Industry. Strategy Science.
Dyer, O., 2021. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt
rollouts.
Géhin, C. and Holman, S.W., 2021. Advances in high‐resolution mass spectrometry applied to
pharmaceuticals in 2020: A whole new age of information. Analytical Science
Advances, 2(3-4), pp.142-156.
Ladas, K., Kavadias, S. and Loch, C.H., 2021. Product selling versus pay-per-use services: a
strategic analysis of competing business models. Available at SSRN 3356458.
Larkin, J., and et.al, 2021. GPs’ perceptions of their relationship with the pharmaceutical
industry: a qualitative study. BJGP open.
Mahase, E., 2021. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots,
finds European Medicine Agency.
Mallapaty, S. and Callaway, E., 2021. What scientists do and don’t know about the Oxford-
AstraZeneca COVID vaccine. Nature, 592(7852), pp.15-17.
Mitchell, A. P and et.al, 2021. Are financial payments from the pharmaceutical industry
associated with physician prescribing? A systematic review. Annals of Internal
Medicine, 174(3), pp.353-361.
Schmuck, R., 2021, July. Business Models in Contemporary Strategic Management.
In International Scientific Conference Strategic Management and Decision
Support Systems in Strategic Management (pp. 120-125).

Sunsandee, N., Phatanasri, S. and Pancharoen, U., 2021. Separation of homogeneous palladium
catalysts from pharmaceutical industry wastewater by using synergistic recovery
phase via HFSLM system. Arabian Journal of Chemistry, 14(4), p.103024.
Wise, J., 2021. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing
interval.
Zhu, X., Ninh, A., Zhao, H. and Liu, Z., 2021. Demand Forecasting with Supply‐Chain
Information and machine learning: Evidence in the Pharmaceutical
Industry. Production and Operations Management.
Online
16 Strategic Planning Models To Consider. 2021. [Online].
https://www.clearpointstrategy.com/strategic-planning-models
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments
for Oxford’s potential new vaccine. 2020. [Online]. Available Through :<
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-
advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-
for-oxfords-potential-new-vaccine.html>